0000950170-24-098717.txt : 20240819 0000950170-24-098717.hdr.sgml : 20240819 20240819174553 ACCESSION NUMBER: 0000950170-24-098717 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240815 FILED AS OF DATE: 20240819 DATE AS OF CHANGE: 20240819 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: von Moltke Lisa CENTRAL INDEX KEY: 0001808592 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37465 FILM NUMBER: 241221998 MAIL ADDRESS: STREET 1: C/O SERESTHERAPEUTICS, INC. STREET 2: 200 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Seres Therapeutics, Inc. CENTRAL INDEX KEY: 0001609809 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 274326290 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 200 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617 945 9626 MAIL ADDRESS: STREET 1: 200 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: Seres Health, Inc. DATE OF NAME CHANGE: 20140603 4 1 ownership.xml 4 X0508 4 2024-08-15 0001609809 Seres Therapeutics, Inc. MCRB 0001808592 von Moltke Lisa C/O SERES THERAPEUTICS, INC. 101 CAMBRIDGE PARK DRIVE CAMBRIDGE MA 02140 false true false false See Remarks true Common Stock 2024-08-15 4 M false 2969 A 21986 D Common Stock 2024-08-16 4 S false 973 0.84 D 21013 D Restricted Stock Units 2024-08-15 4 M false 2969 0 D Common Stock 2969 29688 D Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 11, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units. The price reported in column 4 is a weighted average of the sale prices. These shares were sold in multiple transactions at prices ranging from $0.8414 to $0.890001, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. Executive Vice President and Chief Medical Officer /s/ Thomas J. DesRosier, attorney-in-fact for Lisa von Moltke 2024-08-19